References
- Singapore Cancer Registry Annual Registry Report 2015: National Registry of Diseases Office; [cited 2020 Aug 12]. Available from: https://www.nrdo.gov.sg/docs/librariesprovider3/Publications-Cancer/cancer-registry-annual-report-2015_web.pdf?sfvrsn=1dd97be4_10.
- Lim RB, Loy EY, Lim GH, et al. Gender and ethnic differences in incidence and survival of lymphoid neoplasm subtypes in an Asian population: secular trends of a population-based cancer registry from 1998 to 2012. Int J Cancer. 2015;137(11):2674–2687.
- Jain S, Shah N, Gregory S. Relapsed diffuse large B-cell lymphoma–10 years later. Clin Adv Hematol Oncol. 2011;9(9):704–708.
- Leukaemia Foundation. Diffuse Large B-cell Lymphoma Fact Sheet: Leukaemia Foundation; [cited 2020 Aug 12]. Available from: https://www.leukaemia.org.au/wp-content/uploads/2011/11/Factsheet-Lymphoma-DLBCL.pdf.
- Coiffier B, Thieblemont C, Van Den Neste E, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d’Etudes des Lymphomes de l’Adulte. Blood. 2010;116(12):2040–2045.
- Raut LS, Chakrabarti PP. Management of relapsed-refractory diffuse large B cell lymphoma. South Asian J Cancer. 2014;3(1):66–70.
- Crump M, Neelapu SS, Farooq U, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017;130(16):1800–1808.
- Schuster SJ, Bishop MR, Tam CS, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019;380(1):45–56.
- Schuster SJ, Bishop MR, Tam CS, et al. Long-term follow-up of tisagenlecleucel in adult patients with relapsed or refractory diffuse large B-cell lymphoma: updated analysis of Juliet study. Biol Blood Marrow Transplant. 2019;25(3):S20–S21.
- Schuster SJ, Svoboda J, Chong EA, et al. Chimeric antigen receptor T cells in refractory B-cell lymphomas. N Engl J Med. 2017;377(26):2545–2554.
- Micromedex. Micromedex: Red book online: Micromedex; [cited 2020 Aug 12]. Available from: www.micromedexsolutions.com.
- Department of Statistics Singapore. Death and life expectancy: Department of Statistics Singapore; [cited 2020 April 3]. Available from: https://www.singstat.gov.sg/find-data/search-by-theme/population/death-and-life-expectancy/latest-data.
- Botta L, Dal Maso L, Guzzinati S, et al. Changes in life expectancy for cancer patients over time since diagnosis. J Adv Res. 2019;20:153–159.
- Van Den Neste E, Schmitz N, Mounier N, et al. Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the International CORAL study. Bone Marrow Transplant. 2016;51(1):51–57.
- Gisselbrecht C, Glass B, Mounier N, et al. Salvage regimens with autologous transplantation for relapsed large B-Cell lymphoma in the rituximab era. J Cin Oncol. 2010;28(27):4184–4190.
- Rohatgi A. WebPlotDigitizer San Francisco, California, USA. 2019; [cited 2020 Aug 12]. Available from: http://www.automeris.io/WebPlotDigitizer.
- Guyot P, Ades AE, Ouwens MJ, et al. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol. 2012;12:9.
- Bansal A, Sullivan SD, Lin VW, et al. Estimating long-term survival for patients with relapsed or refractory large B-cell lymphoma treated with chimeric antigen receptor therapy: a comparison of standard and mixture cure models. Med Decis Making. 2019;39(3):294–298.
- Hettle R, Corbett M, Hinde S, et al. 2017. In: The assessment and appraisal of regenerative medicines and cell therapy products: an exploration of methods for review,economic evaluation and appraisal [Internet]; [cited 2020 Aug 12]. Available from: https//www.ncbi.nlm.nih.gov/books/NBK424717.
- Vose JM, Weisenburger DD, Loberiza FR, et al. Late relapse in patients with diffuse large B-cell lymphoma. Br J Haematol. 2010;151(4):354–358.
- Agency for Care Effectiveness. Drug evaluation methods and process guide. 2019; [cited 2020 Aug 12]. Available from: https://www.ace-hta.gov.sg/public-data/our-process-and-methods/ACE%20methods%20and%20process%20guide%20for%20drug%20evaluation%20(20%20Dec%202019).pdf
- Pearce F, Lin L, Teo E, et al. Health technology assessment and its use in drug policies: Singapore. Value Health Reg Issues. 2019;18:176–183.
- Australia Medical Services Advisory Committee. 1519.1- Tisagenlecleucel (CTL109) for treatment of relapsed or refractory diffuse large B-cell lymphoma 2020; [cited 2020 Aug 12]. Available from: http://www.msac.gov.au/internet/msac/publishing.nsf/Content/1519.1-public.
- Ministry of Health Singapore. Consumer price indices (CPI) & household healthcare expenditure. 2020; [cited 2020 Aug 12]. Available from: https://www.moh.gov.sg/resources-statistics/singapore-health-facts/consumer-price-indices-%28cpi%29-household-healthcare-expenditure.
- Maziarz RT, Waller EK, Jaeger U, et al. Patient-reported long-term quality of life after tisagenlecleucel in relapsed/refractory diffuse large B-cell lymphoma. Blood Adv. 2020;4(4):629–637.
- Wang H, Manca A, Crouch S, et al. Health-state utility values in diffuse large B-cell lymphoma. Value in Health. 2018;21:S74.
- Jaglowski S, Hu Z-H, Zhang Y, et al. Tisagnelecleucel Chimeric Antigen Receptor (CAR) T-cell Therapy for Adults with Diffuse Large B-Cell Lymphoma (DLBCL): Real World Experience from the Center for International Blood & Marrow Transplant Research (CIBMTR) Cellular Therapy (CT) Registry. Blood. 2019;134(Supplement_1):766–766.
- Shah NN, Fry TJ. Mechanisms of resistance to CAR T cell therapy. Nat Rev Clin Oncol. 2019;16(6):372–385.
- Zhang J, Medeiros LJ, Young KH. Cancer immunotherapy in diffuse large B-cell lymphoma. Front Oncol. 2018;8:351.
- Lin JK, Muffly LS, Spinner MA, et al. Cost effectiveness of chimeric antigen receptor T-cell therapy in multiply relapsed or refractory adult large B-cell lymphoma. J Clin Oncol. 2019;37(24):2105–2119.
- National Institute for Health and Care Excellence. Tisagenlecleucel-T for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies [TA567]. 2019; [cited 2020 Aug 12]. Available from: http://www.nice.org.uk/guidance/ta567.
- Canadian Agency for Drugs & Technologies in Health. Tisagenlecleucel for Diffuse Large B-cell Lymphoma: Economic Review Report. 2019; [cited 2020 Aug 12]. Available from: http://www.cadth.ca/sites/default/files/pdf/car-t/op0538-tisagenlecleucel-economic-report-DLBCL-jan2019.pdf.
- Roth JA, Sullivan SD, Lin VW, et al. Cost-effectiveness of axicabtagene ciloleucel for adult patients with relapsed or refractory large B-cell lymphoma in the United States. J Med Econ. 2018;21(12):1238–1245.
- Institue for Clinical and Economic Review. CAR-T Therapies: Final Evidence Report; [cited 2020 Aug 12]. Available from: https://icer-review.org/material/car-t-final-report.
- Witzig TE, Geyer SM, Kurtin PJ, et al. Salvage chemotherapy with rituximab DHAP for relapsed non-Hodgkin lymphoma: a phase II trial in the North Central Cancer Treatment Group. Leuk Lymphoma. 2008;49(6):1074–1080.